Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04478071
Recruitment Status : Active, not recruiting
First Posted : July 20, 2020
Last Update Posted : March 14, 2022
Sponsor:
Collaborators:
Akebia Therapeutics Inc.
United States Department of Defense
Information provided by (Responsible Party):
Bentley J. Bobrow, The University of Texas Health Science Center, Houston

Brief Summary:
The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).

Condition or disease Intervention/treatment Phase
Acute Respiratory Distress Syndrome Coronavirus Infection Drug: vadadustat Drug: placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 449 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)
Actual Study Start Date : August 22, 2020
Actual Primary Completion Date : February 16, 2022
Estimated Study Completion Date : April 11, 2022


Arm Intervention/treatment
Experimental: vadadustat Drug: vadadustat
Participants will receive vadadustat once daily for 14 days.
Other Name: AKB-6548

Placebo Comparator: placebo Drug: placebo
Participants will receive matching placebo once daily for 14 days.




Primary Outcome Measures :
  1. Number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ECMO), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the NIAID ordinal scale [ Time Frame: day 14 ]

    National Institute of Allergy and Infectious Disease Ordinal Scale (NIAID-OS):

    8 - Death 7 - Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 6 - Hospitalized, on non-invasive ventilation or high flow oxygen devices 5 - Hospitalized, requiring supplemental oxygen 4 - Hospitalized, not requiring supplemental oxygen - requiring ongoing care (COVID-19 related or otherwise) 3 - Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care 2 - Not hospitalized, limitation on activities and/or requiring home oxygen

    1 - Not hospitalized, no limitations on activities



Secondary Outcome Measures :
  1. Number of participants with a total score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) scale [ Time Frame: day 14 ]

    Modified Sequential Organ Failure Assessment (MSOFA) scale:

    Each of 5 organ systems is given a score of 0 to 4, as detailed below. The MSOFA scale total score is the sum of the score for the 5 organ systems. Discharged patients will be assigned a score of 0 and dead patients a score of 20.

    • Respiratory oxygen saturation(SpO2)/concentration of oxygen that a person inhales(FiO2): 0 (> 400); 1 (≤ 400); 2 (≤ 315); 3 (≤ 235); 4 (≤ 150)
    • Liver: 0 (No scleral icterus or jaundice); 3 (Scleral icterus or jaundice)
    • Cardiovascular, hypotension: 0 (No hypotension); 1 (MAP < 70 mm Hg); 2 (Dopamine ≤ 5 or dobutamine any dose); 3 (Dopamine > 5, Epinephrine ≤ 0.1, Norepinephrine ≤ 0.1); 4 (Dopamine > 15, Epinephrine > 0.1, Norepinephrine > 0.1)
    • Central Nervous System (CNS), Glasgow Coma Score: 0 (15), 1 (13 - 14); 2 (10 - 12); 3 (6 - 9); 4 (< 6)
    • Renal, Creatinine mg/dL: 0 (< 1.2); 1 (1.2 - 1.9); 2 (2.0 - 3.4); 3 (3.5 - 4.9); 4 (> 5.0)


Other Outcome Measures:
  1. Score on the Modified Sequential Organ Failure Assessment (MSOFA) scale [ Time Frame: day 7 ]

    Modified Sequential Organ Failure Assessment (MSOFA) scale:

    Each of 5 organ systems is given a score of 0 to 4, as detailed below. The MSOFA scale total score is the sum of the score for the 5 organ systems. Discharged patients will be assigned a score of 0 and dead patients a score of 20.

    • Respiratory oxygen saturation(SpO2)/concentration of oxygen that a person inhales(FiO2): 0 (> 400); 1 (≤ 400); 2 (≤ 315); 3 (≤ 235); 4 (≤ 150)
    • Liver: 0 (No scleral icterus or jaundice); 3 (Scleral icterus or jaundice)
    • Cardiovascular, hypotension: 0 (No hypotension); 1 (MAP < 70 mm Hg); 2 (Dopamine ≤ 5 or dobutamine any dose); 3 (Dopamine > 5, Epinephrine ≤ 0.1, Norepinephrine ≤ 0.1); 4 (Dopamine > 15, Epinephrine > 0.1, Norepinephrine > 0.1)
    • Central Nervous System (CNS), Glasgow Coma Score: 0 (15), 1 (13 - 14); 2 (10 - 12); 3 (6 - 9); 4 (< 6)
    • Renal, Creatinine mg/dL: 0 (< 1.2); 1 (1.2 - 1.9); 2 (2.0 - 3.4); 3 (3.5 - 4.9); 4 (> 5.0)

  2. Score on the Modified Sequential Organ Failure Assessment (MSOFA) scale [ Time Frame: day 14 ]

    Modified Sequential Organ Failure Assessment (MSOFA) scale:

    Each of 5 organ systems is given a score of 0 to 4, as detailed below. The MSOFA scale total score is the sum of the score for the 5 organ systems. Discharged patients will be assigned a score of 0 and dead patients a score of 20.

    • Respiratory oxygen saturation(SpO2)/concentration of oxygen that a person inhales(FiO2): 0 (> 400); 1 (≤ 400); 2 (≤ 315); 3 (≤ 235); 4 (≤ 150)
    • Liver: 0 (No scleral icterus or jaundice); 3 (Scleral icterus or jaundice)
    • Cardiovascular, hypotension: 0 (No hypotension); 1 (MAP < 70 mm Hg); 2 (Dopamine ≤ 5 or dobutamine any dose); 3 (Dopamine > 5, Epinephrine ≤ 0.1, Norepinephrine ≤ 0.1); 4 (Dopamine > 15, Epinephrine > 0.1, Norepinephrine > 0.1)
    • Central Nervous System (CNS), Glasgow Coma Score: 0 (15), 1 (13 - 14); 2 (10 - 12); 3 (6 - 9); 4 (< 6)
    • Renal, Creatinine mg/dL: 0 (< 1.2); 1 (1.2 - 1.9); 2 (2.0 - 3.4); 3 (3.5 - 4.9); 4 (> 5.0)

  3. Ventilator-free survival [ Time Frame: day 7 ]
  4. Ventilator-free survival [ Time Frame: day 14 ]
  5. Overall survival [ Time Frame: day 7 ]
  6. Overall survival [ Time Frame: day 14 ]
  7. Number of participants with hypotension [ Time Frame: day 7 ]
    Hypotension is defined as Mean Arterial Pressure (MAP) <70 mm Hg or requirement for inotropes or vasopressors to maintain blood pressure.

  8. Number of participants with hypotension [ Time Frame: day 14 ]
    Hypotension is defined as Mean Arterial Pressure (MAP) <70 mm Hg or requirement for inotropes or vasopressors to maintain blood pressure.

  9. Number of participants with acute kidney injury [ Time Frame: day 7 ]
  10. Number of participants with acute kidney injury [ Time Frame: day 14 ]
  11. Time to hospital discharge [ Time Frame: From the time of hospital admission to hospital discharge (about 7 days) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Laboratory-confirmed diagnosis of COVID-19 by detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA by Reverse transcription polymerase chain reaction (RT-PCR) from any specimen respiratory
  • Admitted to the hospital within 36 hours
  • Oxygen saturation of hemoglobin by pulse oximetry at room air ≤94%
  • For patients admitted WITH respiratory symptoms, enrollment must occur within 36 hours of hospital admission. If the patient is admitted to the hospital with normal saturations, but develops respiratory symptoms DURING their hospital stay, enrollment may occur within 24 hours of desaturation to 94% or less on room air
  • Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure

Exclusion Criteria:

  • Hypersensitivity to vadadustat or any of its excipients
  • Placed on mechanical ventilation before randomization
  • Hemoglobin above the gender-specific upper limit of normal (ULN) at randomization: 16 g/dL for females and 18 g/dL for males
  • Patients who have erythrocytosis or polycythemia vera
  • Patient taking Probenecid, lopinavir or ritonavir
  • Women who are pregnant or breastfeeding, or positive pregnancy test before randomization
  • Patients not on maintenance dialysis with eGFC < 31 ml/min
  • Patients who have received a solid organ transplant, heart, kidney, liver or lung
  • Patients who are prisoners
  • Patients who are currently Do Not Resuscitate (DNR) or Do Not Intubate (DNI)
  • Patients with modified Rankin scale of 3 or greater
  • Patient who are currently enrolled in any other interventional clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04478071


Locations
Layout table for location information
United States, Texas
The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030
Sponsors and Collaborators
The University of Texas Health Science Center, Houston
Akebia Therapeutics Inc.
United States Department of Defense
Investigators
Layout table for investigator information
Principal Investigator: Bentley J. Bobrow, MD The University of Texas Health Science Center, Houston
Layout table for additonal information
Responsible Party: Bentley J. Bobrow, Professor, The University of Texas Health Science Center, Houston
ClinicalTrials.gov Identifier: NCT04478071    
Other Study ID Numbers: HSC-MS-20-0395
W81XWH-21-10032 ( Other Grant/Funding Number: United States Department of Defense )
First Posted: July 20, 2020    Key Record Dates
Last Update Posted: March 14, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bentley J. Bobrow, The University of Texas Health Science Center, Houston:
COVID-19
ARDS
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Coronavirus Infections
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Acute Lung Injury
Syndrome
Disease
Pathologic Processes
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders
Infant, Premature, Diseases
Infant, Newborn, Diseases
Lung Injury